Metabolon Selected For Membership In National Cancer Institute Research Group

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Nov. 30, 2005--Metabolon, Inc., a leader in the discovery of biomarkers using metabolomics, today announced it has been selected as a member of the National Cancer Institute's (NCI) Early Detection Research Network (EDRN). Metabolon's second project with NCI but first project as a member of the EDRN will be a collaboration with the University of Michigan to discover novel disease biomarkers for prostate cancer. The collaboration is funded by a grant from NCI as part of the EDRN Chair's Challenge program.

Back to news